Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
SAN DIEGO, April 05, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of immuno-oncology therapies, including off-the-shelf NK- and T-cell-based candidates derived from engineered induced pluripotent cells, and immuno-regulatory therapies, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 [email protected]
